Savara Inc (SVRA)
4.41
-0.04
(-0.90%)
USD |
NASDAQ |
Apr 26, 16:00
4.41
0.00 (0.00%)
After-Hours: 20:00
Savara Research and Development Expense (Quarterly): 12.75M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.75M |
| September 30, 2023 | 13.87M |
| June 30, 2023 | 8.911M |
| March 31, 2023 | 8.738M |
| December 31, 2022 | 7.626M |
| September 30, 2022 | 8.151M |
| June 30, 2022 | 6.418M |
| March 31, 2022 | 5.684M |
| December 31, 2021 | 7.618M |
| September 30, 2021 | 6.532M |
| June 30, 2021 | 7.252M |
| March 31, 2021 | 7.589M |
| December 31, 2020 | 10.16M |
| September 30, 2020 | 5.603M |
| June 30, 2020 | 6.079M |
| March 31, 2020 | 13.20M |
| December 31, 2019 | 8.723M |
| September 30, 2019 | 9.575M |
| June 30, 2019 | 10.46M |
| March 31, 2019 | 10.02M |
| December 31, 2018 | 9.857M |
| September 30, 2018 | 9.509M |
| June 30, 2018 | 9.268M |
| March 31, 2018 | 8.539M |
| December 31, 2017 | 6.436M |
| Date | Value |
|---|---|
| September 30, 2017 | 4.966M |
| June 30, 2017 | 4.164M |
| March 31, 2017 | 2.948M |
| December 31, 2016 | 3.488M |
| September 30, 2016 | 2.142M |
| June 30, 2016 | 1.29M |
| March 31, 2016 | 7.875M |
| December 31, 2015 | -16.78M |
| September 30, 2015 | 7.33M |
| June 30, 2015 | 7.734M |
| March 31, 2015 | 6.042M |
| December 31, 2014 | 4.932M |
| September 30, 2014 | 5.402M |
| June 30, 2014 | 4.82M |
| March 31, 2014 | 4.281M |
| December 31, 2013 | 3.520M |
| September 30, 2013 | 3.102M |
| June 30, 2013 | 2.837M |
| March 31, 2013 | 3.443M |
| December 31, 2012 | 2.112M |
| September 30, 2012 | 1.658M |
| June 30, 2012 | 2.108M |
| March 31, 2012 | 2.210M |
| December 31, 2011 | 1.754M |
| September 30, 2011 | 2.050M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.603M
Minimum
Sep 2020
13.87M
Maximum
Sep 2023
8.681M
Average
8.151M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |
| Oragenics Inc | 11.04M |